Although the fraction of MCL cases showing aberrant NF-κB activation and/or genetic mutations in NF-κB pathway components is presently unknown, it seems that similar to DLBCL, MCL cases can have either the canonical or alternative NF-κB pathway activated [69]. This evidence concerns the gene NFKB1 and mantle cell lymphoma.